# The Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia

> **NCT03288038** · PHASE3 · COMPLETED · sponsor: **Shin Poong Pharmaceutical Co. Ltd.** · enrollment: 382 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Rosuvastatin
- **DRUG:** Ezetimibe

## Key facts

- **NCT ID:** NCT03288038
- **Lead sponsor:** Shin Poong Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-13
- **Primary completion:** 2015-11-19
- **Final completion:** 2015-11-19
- **Target enrollment:** 382 (ACTUAL)
- **Last updated:** 2017-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03288038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03288038, "The Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03288038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*